Seyfried TN and Huysentruyt LC: On the origin of cancer metastasis. Crit Rev Oncog. 18:43–73. 2013. View Article : Google Scholar

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F: Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar

Nowicki TS, Hu-Lieskovan S and Ribas A: Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 24:47–53. 2018. View Article : Google Scholar

Ju X, Zhang H, Zhou Z and Wang Q: Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am J Cancer Res. 10:1–11. 2020.

Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 5:77–106. 2018. View Article : Google Scholar

Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y and Huang C: Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 5:1132020. View Article : Google Scholar

Li CJ, Liao WT, Wu MY and Chu PY: New insights into the role of autophagy in tumor immune microenvironment. Int J Mol Sci. 18:15662017. View Article : Google Scholar

Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunitys roles in cancer suppression and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar

Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science. 342:1432–1433. 2013. View Article : Google Scholar

Dong Y, Sun Q and Zhang X: PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 8:2171–2186. 2017. View Article : Google Scholar

Matsushita M and Kawaguchi M: Immunomodulatory effects of drugs for effective cancer immunotherapy. J Oncol. 2018:86534892018. View Article : Google Scholar

Lin SC, Chu PY, Liao WT, Wu MY, Tsui KH, Lin LT, Huang CH, Chen LL and Li CJ: Glycyrrhizic acid induces human MDA-MB-231 breast cancer cell death and autophagy via the ROS-mitochondrial pathway. Oncol Rep. 39:703–710. 2018.

Song Y, He L, Wang Y, Wu Q and Huang W: Molecularly targeted therapy and immunotherapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (review). Oncol Rep. 44:3–13. 2020.

Chew V, Toh HC and Abastado JP: Immune microenvironment in tumor progression: Characteristics and challenges for therapy. J Oncol. 2012:6084062012. View Article : Google Scholar

Chen SN, Chang R, Lin LT, Chern CU, Tsai HW, Wen ZH, Li YH, Li CJ and Tsui KH: MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities. Int J Environ Res Public Health. 16:15102019. View Article : Google Scholar

Li YT, Lee WL and Tsui KH: Endometrial thickness still presents a best reference to predict endometrial cancer. Taiwan J Obstet Gynecol. 55:148–149. 2016. View Article : Google Scholar

Wu MY, Yiang GT, Cheng PW, Chu PY and Li CJ: Molecular targets in hepatocarcinogenesis and implications for therapy. J Clin Med. 7:2132018. View Article : Google Scholar

Xia A, Zhang Y, Xu J, Yin T and Lu XJ: T cell dysfunction in cancer immunity and immunotherapy. Front Immunol. 10:17192019. View Article : Google Scholar

Mahoney KM, Rennert PD and Freeman GJ: Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 14:561–584. 2015. View Article : Google Scholar

Roncati L: Microsatellite instability predicts response to anti-PD1 immunotherapy in metastatic melanoma. Acta Dermatovenerol Croat. 26:341–343. 2018.

Ribas A: Tumor immunotherapy directed at PD-1. N Engl J Med. 366:2517–2519. 2012. View Article : Google Scholar

Okazaki T and Honjo T: The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27:195–201. 2006. View Article : Google Scholar

Sun H, Sun C and Xiao W: Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine. 65:33–41. 2014. View Article : Google Scholar

Hirsch I, Janovec V, Stranska R and Bendriss-Vermare N: Cross talk between inhibitory immunoreceptor tyrosine-based activation motif-signaling and toll-like receptor pathways in macrophages and dendritic cells. Front Immunol. 8:3942017. View Article : Google Scholar

Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ and Mor A: Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 153:145–152. 2014. View Article : Google Scholar

Okazaki T and Honjo T: PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol. 19:813–824. 2007. View Article : Google Scholar

Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP and Lane PJ: Concurrent OX40 and CD30 ligand blockade abrogates the CD4-driven autoimmunity associated with CTLA4 and PD1 blockade while preserving excellent anti-CD8 tumor immunity. J Immunol. 199:974–981. 2017. View Article : Google Scholar

Homet Moreno B and Ribas A: Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 112:1421–1427. 2015. View Article : Google Scholar

Chiu HC, Li CJ, Yiang GT, Tsai AP and Wu MY: Epithelial to mesenchymal transition and cell biology of molecular regulation in endometrial carcinogenesis. J Clin Med. 8:4392019. View Article : Google Scholar

Tsui KH, Chiang AJ and Yu KJ: Urgent surgical intervention for ruptured ovarian endometrioma. Taiwan J Obstet Gynecol. 51:3282012. View Article : Google Scholar

Dai S, Jia R, Zhang X, Fang Q and Huang L: The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 290:72–79. 2014. View Article : Google Scholar

Joshi S and Durden DL: Combinatorial approach to improve cancer immunotherapy: Rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system. J Oncol. 2019:52450342019. View Article : Google Scholar

Zhang M, Yang J, Zhou J, Gao W, Zhang Y, Lin Y, Wang H, Ruan Z and Ni B: Prognostic Values of CD38⁺CD101⁺PD1⁺CD8⁺ T cells in pancreatic cancer. Immunol Invest. 48:466–479. 2019. View Article : Google Scholar

Nguyen LT and Ohashi PS: Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol. 15:45–56. 2015. View Article : Google Scholar

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar

Reiss KA, Forde PM and Brahmer JR: Harnessing the power of the immune system via blockade of PD-1 and PD-L1: A promising new anticancer strategy. Immunotherapy. 6:459–475. 2014. View Article : Google Scholar

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders R: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar

Koppel C, Schwellenbach H, Zielinski D, Eckstein S, Martin-Ortega M, D'Arrigo C, Schildhaus HU, Rüschoff J and Jasani B: Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. Mod Pathol. 31:1630–1644. 2018. View Article : Google Scholar

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, et al: Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: A potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 27:147–153. 2016. View Article : Google Scholar

Wu Z, Zhang L, Peng J, Xu S, Zhou L, Lin Y, Wang Y and Lu J, Yin W and Lu J: Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting. Cancer Biol Ther. 20:941–947. 2019. View Article : Google Scholar

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P and Rimm DL: Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2:46–54. 2016. View Article : Google Scholar

Ilie M, Hofman V, Dietel M, Soria JC and Hofman P: Assessment of the PD-L1 status by immunohistochemistry: Challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 468:511–525. 2016. View Article : Google Scholar

Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L and Rimm DL: In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 20:2773–2782. 2014. View Article : Google Scholar

Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T and Alix-Panabières C: Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 9:1773–1782. 2015. View Article : Google Scholar

Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N, Li D, Wang R, Dang Y, Hu Z, et al: Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology. 7:e14381112018. View Article : Google Scholar

Acheampong E, Spencer I, Lin W, Ziman M, Millward M and Gray E: Is the blood an alternative for programmed cell death ligand 1 assessment in non-small cell lung cancer? Cancers (Basel). 11:9202019. View Article : Google Scholar

Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA and Wasik MA: Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 105:20852–20857. 2008. View Article : Google Scholar

Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP and Lin Y: Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 17:854–855. 2018. View Article : Google Scholar

Holz MK: The role of S6K1 in ER-positive breast cancer. Cell Cycle. 11:3159–3165. 2012. View Article : Google Scholar

Sridharan S and Basu A: Distinct roles of mTOR targets S6K1 and S6K2 in breast cancer. Int J Mol Sci. 21:11992020. View Article : Google Scholar

Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO and Parsa AT: PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 28:306–312. 2009. View Article : Google Scholar

Jiang X, Zhou J, Giobbie-Hurder A, Wargo J and Hodi FS: The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 19:598–609. 2013. View Article : Google Scholar

Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A, Al-Alwan M, Hendrayani SF, Manogaran P, Alaiya A, Al-Tweigeri T, et al: Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: Role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 12:R482010. View Article : Google Scholar

Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, et al: Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75:5034–5045. 2015. View Article : Google Scholar

Uhercik M, Sanders AJ, Owen S, Davies EL, Sharma AK, Jiang WG and Mokbel K: Clinical significance of PD1 and PDL1 in human breast cancer. Anticancer Res. 37:4249–4254. 2017.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 520:373–377. 2015. View Article : Google Scholar

Lv S, Wang S, Qiao G, Wang X, Zhou X, Yan F, Li Y, Wang S, Morse MA, Hobeika A, et al: Functional CD3⁺CD8⁺PD1⁻ T cell accumulation and PD-L1 expression increases during tumor invasion in DCIS of the breast. Clin Breast Cancer. 19:e617–e623. 2019. View Article : Google Scholar

Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, et al: Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 69:25–34. 2016. View Article : Google Scholar

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al: PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2:361–370. 2014. View Article : Google Scholar

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, et al: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 23:2965–2970. 2014. View Article : Google Scholar

Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D and van Laere S: PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 6:13506–13519. 2015. View Article : Google Scholar

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D and Bertucci F: Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 6:5449–5464. 2015. View Article : Google Scholar

Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, et al: Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 146:15–24. 2014. View Article : Google Scholar

Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D and Gillanders WE: The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 139:667–676. 2013. View Article : Google Scholar

Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, Wang J, Yuan F, Sun L, Yu Q, et al: PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 63:395–406. 2014. View Article : Google Scholar

Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar

Hasan A, Ghebeh H, Lehe C, Ahmad R and Dermime S: Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets. 15:1211–1225. 2011. View Article : Google Scholar

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM and Topalian SL: Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 42:587–600. 2015. View Article : Google Scholar

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar

Wang Y, Zhang X, Yang L, Xue J and Hu G: Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. J Bone Oncol. 11:27–32. 2018. View Article : Google Scholar

Stenehjem DD, Tran D, Nkrumah MA and Gupta S: PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther. 11:5973–5989. 2018. View Article : Google Scholar

Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM and Cranmer LD: Response to PD1 inhibition in conventional chondrosarcoma. J Immunother Cancer. 6:942018. View Article : Google Scholar

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, et al: T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 10:eaan33112018. View Article : Google Scholar

Pusztai L, Karn T, Safonov A, Abu-Khalaf MM and Bianchini G: New strategies in breast cancer: Immunotherapy. Clin Cancer Res. 22:2105–2110. 2016. View Article : Google Scholar

Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467. 2016. View Article : Google Scholar

Emens LA: Breast cancer immunobiology driving immunotherapy: Vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 12:1597–1611. 2012. View Article : Google Scholar

Badr NM, Berditchevski F and Shaaban AM: The immune microenvironment in breast carcinoma: Predictive and prognostic role in the neoadjuvant setting. Pathobiology. 87:61–74. 2020. View Article : Google Scholar

Tan W, Yang M, Yang H, Zhou F and Shen W: Predicting the response to neoadjuvant therapy for early-stage breast cancer: Tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 10:4333–4347. 2018. View Article : Google Scholar

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, et al: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 22:1499–1509. 2016. View Article : Google Scholar

Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY and Levy R: Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci USA. 112:E966–E972. 2015. View Article : Google Scholar

Garcia-Aranda M and Redondo M: Immunotherapy: A challenge of breast cancer treatment. Cancers (Basel). 11:18222019. View Article : Google Scholar

Chawla A, Philips AV, Alatrash G and Mittendorf E: Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology. 3:e283252014. View Article : Google Scholar

Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, Azad BB, Pomper MG and Nimmagadda S: A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 7:10215–10227. 2016. View Article : Google Scholar

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar

Gibson J: Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol. 16:e2642015. View Article : Google Scholar

Ott PA, Hodi FS and Robert C: CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 19:5300–5309. 2013. View Article : Google Scholar

Kerr KM and Hirsch FR: Programmed death ligand-1 immunohistochemistry: Friend or foe? Arch Pathol Lab Med. 140:326–331. 2016. View Article : Google Scholar

Voutsadakis IA: Immune blockade inhibition in breast cancer. Anticancer Res. 36:5607–5622. 2016. View Article : Google Scholar

Yi KH and Chen L: Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev. 229:145–151. 2009. View Article : Google Scholar